NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Virax Biolabs Group Limited (VRAX) Stock Analysis

Virax Biolabs Group Limited (VRAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VRAX

$2.63

+$0.06 (+2.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VRAX with… →

VRAX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.54
Previous Close
$2.56
Day's Range
2.54–2.64
52-Week Range
2.50–21.75
Volume
21.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.35
Valuation
Market Cap
$2.09M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
168.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−13.01
Financials (FY)
Revenue (FY)
$12.42K+96.22%
Net Income (FY)
−$5.02M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
796.99K
1-Year Return
−82.70%
Dividend and dates
Avg Volume
1.80M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VRAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.65%
2025−84.62%
2024+54.11%
2023−80.00%
2022 (partial year)−95.99%

As of September 4, 2026.

VRAX Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$12.42K−$5.02M−40439.1%
2024$6.33K−$6.06M−95739.2%
2023$156.42K−$6.73M−4304.8%
2022$8.56K−$5.46M−63748.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$12.42K$7.69K−$6.40M−$5.02M−40439.1%
2024$6.33K−$53.07K−$6.08M−$6.06M−95739.2%
2023$156.42K$50.59K−$6.14M−$6.73M−4304.8%
2022$8.56K−$1.37K−$5.73M−$5.46M−63748.3%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

VRAX Valuation vs Biotechnology Median

Median of 656 stocks
MetricVRAXBiotechnology medianvs median
P/S ratio168.4015.2611.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Virax Biolabs Group Limited (VRAX) at $2.09M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 26.

The 52-week range on file runs from $2.50 to $21.75. The most recent close on file for VRAX is $2.63, dated September 4, 2026. That is +$0.06 (+2.54%) against the previous close. The latest close sits 5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $12.42K. That is +96.22% against the prior fiscal year, when revenue was $6.33K. The same year closed with a net loss of $5.02M. The reported profit margin is 0%. Trailing earnings per share are −13.01.

Across the 4 fiscal years on file, revenue moves from $8.56K in 2022 to $12.42K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 168.4. On price-to-sales that is 11 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.36. Annualized volatility over the trailing 4 years is 173.48%. The trailing one-year price return is −82.70%. Across 3 years the annualized return works out at −69.22%.

Growth & Income

No dividend is on file for VRAX.

So far in 2026 the price is −69.65%. The strongest complete calendar year on file is 2024 at +54.11%; the weakest is 2025 at −84.62%. Of the 3 complete calendar years on file, 1 finished higher.

Peer Comparison

Virax Biolabs Group Limited (VRAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Virax Biolabs Group Limited VRAX $2.09M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Virax Biolabs Group Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Virax Biolabs Group Limited

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Visit website →